PL371263A1 - Sposoby wytwarzania krystalicznej i amorficznej soli wapniowej mupirocyny - Google Patents

Sposoby wytwarzania krystalicznej i amorficznej soli wapniowej mupirocyny

Info

Publication number
PL371263A1
PL371263A1 PL02371263A PL37126302A PL371263A1 PL 371263 A1 PL371263 A1 PL 371263A1 PL 02371263 A PL02371263 A PL 02371263A PL 37126302 A PL37126302 A PL 37126302A PL 371263 A1 PL371263 A1 PL 371263A1
Authority
PL
Poland
Prior art keywords
processes
preparing crystalline
mupirocin calcium
amorphous mupirocin
amorphous
Prior art date
Application number
PL02371263A
Other languages
English (en)
Inventor
Lorant Gyuricza
Sos Erzsebet Meszaros
Csaba Szabo
Claude Singer
Original Assignee
Biogal Gyogyszergyar Rt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogal Gyogyszergyar Rt filed Critical Biogal Gyogyszergyar Rt
Publication of PL371263A1 publication Critical patent/PL371263A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL02371263A 2001-12-28 2002-11-06 Sposoby wytwarzania krystalicznej i amorficznej soli wapniowej mupirocyny PL371263A1 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US34411701P 2001-12-28 2001-12-28
US34411801P 2001-12-28 2001-12-28
US34818302P 2002-01-11 2002-01-11
US34814202P 2002-01-11 2002-01-11
US36072102P 2002-03-01 2002-03-01
US36873502P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
PL371263A1 true PL371263A1 (pl) 2005-06-13

Family

ID=27739507

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02371263A PL371263A1 (pl) 2001-12-28 2002-11-06 Sposoby wytwarzania krystalicznej i amorficznej soli wapniowej mupirocyny

Country Status (14)

Country Link
US (2) US7737177B2 (pl)
EP (1) EP1455769A4 (pl)
JP (1) JP2005516984A (pl)
KR (1) KR20040075857A (pl)
CN (1) CN1625394A (pl)
AU (1) AU2002365431A1 (pl)
CA (1) CA2460970C (pl)
DE (1) DE20220885U1 (pl)
HR (1) HRP20040642A2 (pl)
HU (1) HUP0600679A2 (pl)
IL (1) IL162457A0 (pl)
MX (1) MXPA04006391A (pl)
PL (1) PL371263A1 (pl)
WO (1) WO2003065975A2 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate
US7589128B2 (en) * 2004-06-01 2009-09-15 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for preparation of amorphous form of a drug
US8158139B2 (en) * 2004-07-12 2012-04-17 Taro Pharmaceuticals North America, Inc. Topical gel formulation comprising organophosphate insecticide and preparation thereof
US8012498B2 (en) 2004-07-12 2011-09-06 Sandhya Goyal Topical gel formulation comprising organophosphate insecticide and preparation thereof
KR100829989B1 (ko) * 2005-03-28 2008-05-16 주식회사 팬택 초광대역 무선 접속망에서의 다중접속 디지털 통신방법
US7560445B2 (en) * 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
GB2441328A (en) 2006-08-30 2008-03-05 Alpharma Aps A method for obtaining mupirocin calcium
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN107963991A (zh) * 2017-12-29 2018-04-27 成都百裕制药股份有限公司 一种无定形托伐普坦的生产方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643240A1 (de) 1966-09-16 1971-06-24 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer racemischer oder optisch aktiver 1-Phenoxy-2-aminoalkane
GB1395907A (en) 1971-06-12 1975-05-29 Beecham Group Ltd Antibiotics
US3977943A (en) 1971-06-12 1976-08-31 Beecham Group Limited Antibiotics
US4071536A (en) 1971-06-12 1978-01-31 Beecham Group Limited Antibiotics
JPS5270083A (en) 1975-12-04 1977-06-10 Yoshitomi Pharmaceut Ind Ltd Manufacture of an antibiotics, trans-pseudomonic acid
GB1577730A (en) 1976-10-23 1980-10-29 Beecham Group Ltd Treatment of infections with pseudomonicacid salts or esters thereof
GB1577545A (en) 1977-07-27 1980-10-22 Beecham Group Ltd Treatment of swine dysenter
CA1103264A (en) 1977-09-30 1981-06-16 Norman H. Rogers Purification of pseudomonic acid
CA1115699A (en) 1978-05-20 1982-01-05 Alan D. Curzons Lithium pseudomonate and its preparation
CA1196284A (en) 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8415579D0 (en) 1984-06-19 1984-07-25 Beecham Group Plc Compounds
GB8428952D0 (en) * 1984-11-16 1984-12-27 Beecham Group Plc Formulations
GB8530796D0 (en) 1985-12-13 1986-01-22 Beecham Group Plc Pharmaceutical composition
IE59628B1 (en) 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
US5594026A (en) 1990-12-11 1997-01-14 Smithkline Beecham Group P.L.C. Polymorphs of crystalline mupirocin
US5292892A (en) 1991-05-07 1994-03-08 Sankyo Company, Limited Anti-bacterial compound and pharmaceutical compositions thereof
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
CZ112499A3 (cs) 1996-10-01 1999-08-11 Smithkline Beecham Corporation Použití mupirocinu k výrobě léčiva pro léčbu bakteriálních infekcí spojených s kolonizací nosohltanu patogenními organismy
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
DE19849924A1 (de) * 1998-10-29 2000-05-04 Degussa Verfahren zur Abtrennung organischer Säuren aus wäßrigen Lösungen
US6245921B1 (en) 1999-02-03 2001-06-12 Biogal Gyogyszergyar Rt. Process for the isolation of pseudomonic acid A from pseudomonic acid complex-containing culture broth
HUP0300363A2 (hu) 1999-02-03 2004-06-28 BIOGAL Gyógyszergyár Rt. Eljárás pszeudomonsav A előállítására mikrobiológiai eljárás segítségével
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
IL137363A (en) 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
PL374255A1 (pl) * 2001-06-21 2005-10-03 Biogal Gyogyszergyar Rt Metabolicznie kontrolowany sposób fermentacji do wytwarzania kwasu pseudomonowego
IL150907A (en) * 2002-07-25 2007-07-04 Stephan Cherkez Process for the preparation of stable amorphous calcium pseudomonate

Also Published As

Publication number Publication date
AU2002365431A1 (en) 2003-09-02
US20040024052A1 (en) 2004-02-05
CA2460970C (en) 2005-10-18
CN1625394A (zh) 2005-06-08
US20080249322A1 (en) 2008-10-09
JP2005516984A (ja) 2005-06-09
DE20220885U1 (de) 2004-06-24
HRP20040642A2 (en) 2005-10-31
WO2003065975A3 (en) 2004-02-19
IL162457A0 (en) 2005-11-20
EP1455769A4 (en) 2004-09-22
CA2460970A1 (en) 2003-08-14
KR20040075857A (ko) 2004-08-30
EP1455769A2 (en) 2004-09-15
US7737177B2 (en) 2010-06-15
WO2003065975A2 (en) 2003-08-14
HUP0600679A2 (en) 2008-06-30
MXPA04006391A (es) 2004-10-04

Similar Documents

Publication Publication Date Title
GB9906715D0 (en) Compositions for promoting growth
GB0014079D0 (en) Orthopaedic implant
PT1299323E (pt) Adubo com libertação controlada e método para a sua produção
HUP0500599A3 (en) Calcium metasilicates and methods for making the same
EP1425279A4 (en) PROCESS FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES
HUP9903634D0 (en) Process for producing amorphous atorvastatin calcium salt
IL159626A0 (en) Crystalline forms of atorvastatin calcium and processes for the preparation thereof
AU2002228598A1 (en) Methods and devices for high throughput crystallization
PL368984A1 (pl) Sposób otrzymywania krystalicznej postaci imipenemu
IL162457A0 (en) Processes for preparing crystalline and amorphous mupirocin calcium
EP1534727A4 (en) CRYSTALLINE AND AMORPH FORMS OF BETA-L-2'-DESOXYTHYMIDINE
EP1389462A4 (en) AMORPHIC CEFIDITIVE PIVOXIL COMPOSITION AND METHOD FOR THE PRODUCTION THEREOF
AU2002253642A1 (en) Amorphous cefditoren pivoxil composition and process for producing the same
AU2003260078A8 (en) Crystalline and amorphous forms of (s) -repaglinide and the processes for preparation thereof
IL150907A0 (en) Stable amorphous calcium pseudomonate and process for the preparation thereof
HUP0501093A2 (en) Process for the isolation of crystalline imipenem
AU2002356423A1 (en) Process for the preparation of amorphous atorvastatin calcium
GB0129273D0 (en) Crystalline drug form
AU2003246260A1 (en) Calcium silicate hardened article
GB0120808D0 (en) Crystalline material
GB2385583B8 (en) Flower box
GB0123517D0 (en) Growing system
AU2001280083A1 (en) Process for the production of atorvastatin calcium in amorphous form
CZ20011696A3 (cs) Způsob výroby amorfního křemičitanu hlinito-sodného
GB0108226D0 (en) Novel crystalline forms

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)